Current Report Filing (8-k)
February 10 2022 - 9:13AM
Edgar (US Regulatory)
0001441693
false
0001441693
2022-02-07
2022-02-07
0001441693
dei:FormerAddressMember
2022-02-07
2022-02-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): February 7, 2022
MARRONE
BIO INNOVATIONS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
001-36030
|
|
20-5137161
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
7780-420
Briar Creek Parkway, Raleigh, NC 27617
(Address
of Principal Executive Offices, and Zip Code)
(530)
750-2800
Registrant’s
Telephone Number, Including Area Code
1540
Drew Avenue, Davis, CA 95618
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.00001 par value
|
|
MBII
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
(e)
On
February 7, 2022, the Board of Directors (the “Board”) of Marrone Bio Innovations, Inc. (the “Company”), upon
recommendation of the Compensation Committee of the Board (the “Committee”) approved of awards under a newly implemented
long-term incentive program (“LTIP”) for the Company’s principal executive officer and principal financial officer
(“PEOs”) and other Company executives and employees (the “Awards”). The Awards for the PEOs were comprised of
a mix of stock options (“Options”) and restricted stock units (“RSUs”), with total grant value and weighting
ascribed by the Committee as follows:
|
|
Options
|
|
|
RSUs
|
|
|
Total Award Value
|
|
|
Weighting (Option/RSUs)
|
|
Kevin Helash
|
|
|
417,273
|
|
|
|
178,831
|
|
|
$
|
459,000
|
|
|
|
70%/30
|
%
|
Sue Cheung
|
|
|
185,555
|
|
|
|
65,064
|
|
|
$
|
167,000
|
|
|
|
70%/30
|
%
|
The
Awards were granted subject to the terms of the Company’s 2013 Stock Incentive Plan (the “Plan”). Each award vests
in equal monthly installments over three years, subject to the recipient’s continued employment by the Company through the applicable
vesting date, provided that, in lieu of the terms of any change in control agreement in place between the Company and the recipient,
in the event that any recipient is terminated without Cause (as defined in the recipient’s Change In Control Agreement) or resigns
for Good Reason (as defined in the recipient’s Change In Control Agreement) within twelve months of a Change in Control (as defined
in the recipient’s Change In Control Agreement), 50% of the unvested portion of each Award will become immediately vested.
The
Committee recommended the adoption of the LTIP and the issuance of the Awards in order to provide recipients market-competitive grants
and to promote their long-term vested interest in the success of the Company and in consideration of information provided by Pearl Meyer,
an independent compensation consultant engaged by the Committee in 2021 to survey the latest trends and best practices in relation to
the compensation of executive officers among the Company’s peer group.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MARRONE
BIO INNOVATIONS, INC.
|
|
|
Date:
February 10, 2022
|
By:
|
/s/
Linda V. Moore
|
|
Name:
|
Linda
V. Moore
|
|
Title:
|
Executive
Vice President, General Counsel and Secretary
|
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024